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- Patients with Marginal zone lymphoma (MZL) who experience progressive disease within 24 months from 
initial systemic therapy (POD24) have a significant increase of the risk of Death. 
- Association of POD24 with survival is confirmed for the main MZL subtypes 
 




Marginal zone Lymphomas (MZL) are indolent B cell non Hodgkin Lymphoma (INFL) and 
have a heterogeneous clinical behavior. Recently time to progression shorter than 24 months 
(POD24) was identified to stratify overall survival (OS) in follicular NHL and in INFL. Here we 
examined the ability of POD24 to predict subsequent OS in a large, international cohort of 
MZL as part of the NF10 prospective international registry (NCT02904577) headed by 
Fondazione Italiana Linfomi (FIL). POD24 was calculated only for MZL patients requiring 
immediate therapy and was defined as experiencing lymphoma progression within 24 months 
from diagnosis. Among the 1,325 patients enrolled in the NF10 study we identified 321 pts 
with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall 
POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% 
with a HR of 19.5 (95%CI 8.4-45) compared with patients without POD24 (3 yr OS 95%). 
Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal 
MZL. 
Assessment of POD24 stratifies subsequent outcome in MZL and identifies high risk 
population. 
 




Marginal zone Lymphomas (MZLs) originate from mature B lymphocytes, and include splenic, 
nodal and extranodal subtypes (SMZL, NMZL, ENMZL)1. Despite their indolent course a high 
heterogeneity of clinical behavior exists that warrants accurate tools to estimate the risk of 
relapse, progression or death in the individual patient. A prognostic index to foresee the 
outcome of all patients with MZL is missing but subtypes specific indexes have been 
proposed and validated for ENMZL 2 and for SMZL 3,4. Recently the analysis of progression 
free survival (PFS) has been used to identify surrogate endpoints in B-cell NHLs, with 
Progression of Disease at 24 months (POD24) identified to stratify overall survival (OS) in 
follicular NHL.5 Association of POD24 with OS has been confirmed in FL,  Mantle Cell 
Lymphomas,  Diffuse Large B-Cell and in peripheral T-cell Lymphoma and recently also in 
Indolent non follicular B-cell lymphomas (INFL).6–9 
The NF10 Project was started in 2010 as a prospective observational study specifically 
conceived to investigate the outcome of INFL. We examined the ability of POD24 to predict 
subsequent OS in the large MZL cohort of patients enrolled in the NF10 study. 
 
Methods:  
Consecutive adult patients with newly diagnosed, histologic confirmed diagnosis of INFL were 
eligible for the NF10 study without any exclusion criteria and including SMZL, ENMZL, NMZL, 
lymphoplasmacytic lymphoma (LPL), Small Lymphocytic Lymphoma (SLL), and CD5-negative 
low-grade B cell lymphoma. Histologic diagnosis was required on tissue or on bone marrow 
biopsy and was based on local assessment. Patients were managed based on local 
institutional guidelines; treatment was left to physician discretion and was analyzed according 
to an intent to treat principle;. Watch and wait (WW) was defined as the decision not to treat 
For personal use only.on August 4, 2019. by guest  www.bloodjournal.orgFrom 
 
 5 
patients and by the absence of treatment within the first 3 months from the date of diagnosis. 
The definition of systemic therapy was applied to the use of systemic chemotherapy and of 
anti-CD20 monoclonal antibody alone or in combination with one or more chemotherapy 
agent; the use of antibiotics, radiotherapy or splenectomy were not considered as systemic 
therapies. The main aim of the current study was to validate the prognostic role of time to 
progression on the subgroup of patients with MZL who received immediate systemic therapy.  
 
The main endpoint of this study was Overall Survival (OS); secondary endpoints were PFS 
and cause specific survival (CSS) 10. POD24 was defined as experiencing lymphoma 
progression within 24 months from diagnosis. Survival analysis according to POD24 was 
calculated only for patients with events within 24 months (early progressors) or for those with 
at least 24 months of follow-up in case no POD24 defining event was reported (not early 
progressor). The OS was calculated from risk-defining event for early progressors; for 
patients without early progression os was computed starting at 24 months from diagnosis, to 
reduce the effect of early progressive disease patients. Patients censored or died before 24 
months were excluded from analysis. The study was approved by local ethic committees at 
any active center and signed consent form was mandatory for all enrolled patients.  
 
Results and discussion 
Between July 2010 and July 2018, 1,325 INFL cases have been registered in the NF10 study 
by 65 centers in Europe and South America. Demographic and clinical characteristics are 
summarized in table 1. Overall, 321 patients who received immediate systemic therapy and 
who had an adequate follow-up were identified as the main study population. The median 
follow-up was 43 months (range 1-92). Five-year PFS was 64% (95% CI 56 to 71%). Salvage 
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treatment of patients with progressive disease was immunochemotherapy in 46 cases (55%), 
radiotherapy in 6 (7%), observation in 7(8%). High dose therapy followed by autologous stem 
cell transplant (ASCT) was reported in 3 cases and in 23 cases it was not possible to obtain 
details on salvage therapy (27%). Overall 31 patients died; progressive disease was reported 
as the cause of death in 19/31 cases (61%). Five-year OS was 88% (95% CI 83 to 92%). 
POD24 was reported in 59/321 patients (18%). Three-year OS for patients with POD24 was 
53% (95%CI 37-67%) with a HR of 19.5 (95%CI 8.4 – 45.4) when compared to patients 
without POD24 (88%%, 95%CI 89-98%) (Figure1). Association of POD24 with OS was also 
confirmed with a lower HR, for patients who were not immediately treated (POD24 rate 25%, 
HR for OS 2.69 CI95% 1.04 to 6.92). The association of POD24 with OS was confirmed in 
ENMZL, SMZL and Diss-MZL subgroups (Figure 1). Our data confirm the strong association 
of time to progression with OS as seen for FL and, more recently, in a study of INFL by the 
University of Iowa/Mayo Clinic9. Differently from the US series our study was focused on a 
homogeneous population of MZL patients prospectively recruited in an international study 
who were treated with systemic chemo and/or immunotherapy. Notwithstanding small 
differences between the two studies and the use of two slightly different endpoints, both 
support the strong association of time to progression with the risk of death.   
Recent data on FL suggest that early events could be enriched with transformed cases with 
more aggressive behavior.11 In our study 66% of deaths for POD24 patients were referred to 
lymphoma progression and higher mortality of early relapsed was confirmed also by CSS 
analysis; moreover among the 90 patients who experienced progressive disease we were 
able to identify 7 patients with histologically transformed MZL all of whom were counted as 
POD24 cases. Thus also if the rate of transformation in our series was low compared to other 
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reported series 12,13, our report suggests that histological transformation (HT) might play a role 
in defining the quality of early events.  
Another issue with POD24 patients is about salvage treatment. In follicular lymphomas, two 
recent reports suggested that the use of ASCT might be a better option compared to 
conventional salvage therapies for early relapser14,15 . In MZL the efficacy of ASCT is 
controversial and its role as salvage therapy for POD24 patients remains an open research 
question. Indeed, very few POD24 patients were treated with ASCT in our study.  
 
The finding of early progression (POD24) as strong marker of poor outcome is useful but its 
clinical utility to support initial treatment choice is limited. Logistic univariate analysis adjusted 
by treatment modality (immunochemotherapy vs chemotherapy without rituximab) identified 
clinical and laboratory parameters associated with higher risk of POD24 (age >60,  
performance status, systemic symptoms, bone marrow involvement, low serum albumin, 
elevated LDH, Beta2Microglobulin, low Hemoglobin, reduced Platelet count, low Absolute 
lymphocyte count). Among tested prognostic scores  FLIPI predicted the risk of POD24(12% 
and 27% for 0-2 and 3-5 risk factors; p=0.001). Future research efforts should focus on the 
identification of these high risk patients at the time of diagnosis, in order to enable 
personalized therapy. 
In conclusion assessment of POD24 predicts subsequent outcome in MZL in need of therapy 
and its association with OS is confirmed for the main MZL subtypes. Our data have important 
implications for the management of patients with MZL and for a better understanding of the 
disease.  
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Table 1 - Characteristic of the 321 MZL patients we received immediate systemic therapy 
(study population) and comparison with MZL patients enrolled in the NF10 who did not 
receive immediate therapy. 
 
Factor   Missing  Untreated (%) Treated (%) P 
Total   286 321  
MZL(*)  ENMZL - 96 (34) 146 (46) <0.001 
              SMZL - 122(43) 84 (26)  
              NMZL - 30 (10) 32 (10)  
              DissMZL - 38 (13) 59 (18)  
Age  > 60 years - 203 (71) 202 (62) 0.039 
ECOG PS  >1 3 8 (3) 21 (7) 0.036 
Symptoms B 3 19 (7) 66 (21) <0.001 
Hb < 12g/dl  3 73 (26) 129 (40) <0.001 
Platelets  < 150x109/ul 5 97 (34) 90 (28) 0.094 
LDH  > UNL 30 61(23) 96 (31) 0.049 
B2M  > UNL 17 96 (41) 156 (60) <0.001 
LN size  > 6cm 61 8 (3) 34 (11) <0.001 
Albumin  < 3.5 g/dl 74 15 (8) 51 (22) <0.001 
HBV 
serology 
+ 12 23 (8) 25 (9) 0.88 
HCV 
serology 
+ 27 35 (12) 
 
67 (21) 0.012 
Treatment      
 Watch & wait 7 286(100) -  
 Alk-Mono - - 16 (5)  
 R-Mono - - 30 (9)  
    R-Alkylating - - 83 (26)  
 R-CHOP - - 48 (15)  
 R-Bendamustine - - 112 (35)  
 R-Fludarabine - - 3 (1)  
 Other - - 21 (6)  
Legend to table: (*) Eligible patients were classified as SMZL, ENMZL and NMZL according to local pathologic 
diagnosis. Patients with histologic features consistent with MZL with concomitant involvement of the marrow 
and/or spleen and/or lymph nodes and/or extranodal sites but lacking the diagnostic features of splenic, nodal or 
extranodal MZL were categorized as disseminated MZL (dissMZL). MZL: Marginal Zone Lymphoma; ENMZL: 
Extranodal MZL; SMZL: Splenic MZL; NMZL: Nodal MZL; Diss MZL: Disseminated MZL; PS: Performance 
Status; Hb: Hemoglobin; LDH: Lactate dehydrogenase; B2M: beta2-microglobulin; LN: lymph node; HBV: 
Hepatitis B virus; HCV: Hepatitis C virus; Alk: alkylating agent; R: Rituximab 
 
 





Figure 1 Overall survival by POD24 and by marginal zone lymphoma subtypes 
Overall survival from risk-defining event after diagnosis in patients with MZL who were 
immediately treated after diagnosis a) Patients with MZL: POD24 rate 18%; 3-yr OS POD24 
achieve 95% vs fail 53%, p<0.001 [HR 19.5; 95%CI 8.40-45.4], b) Patients with SMZL: POD 
rate 25%: 3-yr OS POD24 achieve 95% vs fail 44%, p<0.001; c) Patients with diss-MZL: POD 
rate 20%: 3-yr OS POD24 achieve 93% vs fail 33%, p<0.001; d) Patients with ENMZL: POD 
rate 16%: 3-yr OS POD24 achieve 98% vs fail 71%, p<0.001. Association of POD24 with OS 
could not be assessed for nodal MZL patients because too few events have been reported in 
this subgroup to do any inference. Legend to figure: MZL, Marginal Zone Lymphoma; SMZL 
Splenic MZL; Diss MZL, Disseminated MZL; ENMZL, Extranodal MZL. 
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